new drugs for psoriasis might be lifesavers
Related Articles
- Easing trepidation about biologies. Kapes, Beth // Dermatology Times;Sep2004 Supplement, Vol. 25, pS27
Discusses the benefits offered by biologics for psoriasis treatment. Affirmation of David E. Cohen that the new biologic products offer advantages over existing medications; Presentation of new biologics that are approved for treating moderate to sever psoriasis and psoriatic arthritis;...
- Biologies for psoriasis pulling their weight. Wilson, Fred // Dermatology Times;Sep2004 Supplement, Vol. 25, pS18
The article discusses the effect of biologic therapy on psoriatic patients. Consideration of Amevive as the first biologic drug approved for moderate to severe plaque psoriasis; Elaboration on the effects of the drug, Raptiva; Responses of patients to Remicade infusions.
- Study shows leading drugs' effectiveness against psoriasis. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS34
The article discusses the effectiveness of leading drugs against psoriasis. Statement of Craig L. Leonardi, associate dermatologist of St. Louis University in Missouri, on the effectiveness of Biogen's alefacept; Clarifications on the length of effectiveness of some drugs; Discussion on the...
- tazarotene. // Royal Society of Medicine: Medicines;2002, p523
The article presents information on tazarotene which is chemically a derivative of retinol or vitamin A. This drug can be used to treat mild to moderate plaque psoriasis. Administration is by topical application. It should not be used in pregnancy or breast-feeding. Patients should wash hands...
- Treating Itch in Psoriasis. Dawn, Aerlyn; Yosipovitch, Gil // Dermatology Nursing;Jun2006, Vol. 18 Issue 3, p227
The article presents a study on the effective management and treatment of psoriatic itch. Patients with chronic pruritus often have difficulty sleeping, problems concentrating, lowered sex drive, and depression. The treatments recommended for psoriatic itch are tar products, topical...
- Biologies open new, long-term approaches to doctors; patients face economic challenges. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS44
Focuses on the biologic treatments for psoriasis. Analysis on the biologics that won approval for treating the disease; Information on other biologics that are still unapproved; Affirmation on the economic challenges faced by patients with the new drugs in the market.
- Biologic modalities for psoriasis emerging at lightning speed. Schwanke, Jane // Dermatology Times;Sep2004 Supplement, Vol. 25, pS45
Discusses the emergence of biologic drugs for treating psoriasis. Issues related to cost and insurance coverage; Statement of Craig Leonardi, associate clinical professor of dermatology in St. Louis University, on the ability of the current systematic treatments to control the disease; Selection...
- New oral psoriasis agents show promise. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS13
Introduces different oral treatment for psoriasis. Side effects of the retinoid, an oral tazarotene; Acquisition of a new oral formulation of the drug BG-12 oral fumarate by Biogen; Discussion on the effects of oral pimecrolimus on psoriatic patients.
- Physician says TNF-a antagonists very safe, overall. Guttman, Cheryl // Dermatology Times;Sep2004 Supplement, Vol. 25, pS33
Reports that TNF-a antagonists are safe for psoriatic patients. Presentation of several antagonists safe for psoriatic therapy; Discussion on the risks of serious infections and malignancies related to the immunosuppressive activity of the TNF-a antagonist; Effects on patients after treated with...
